QI
ADAP

QS Investors’s Adaptimmune Therapeutics ADAP Stock Holding History

QS Investors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-138,000
Closed -$733K – 1098
2021
Q1 		$733K Buy
+138,000
New +$790K 0.01% 630

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

QS Investors's ADAP Position: Q2 2021 in Review

QS Investors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2021, closing a stake of 138,000 shares — an estimated $733K sold.

QS Investors first reported a position in ADAP in Q1 2021 and held it in 1 quarter. The position peaked at $733K in Q1 2021. 82 funds tracked by Wall St. Rank hold ADAP as of Q2 2021.

  • QS Investors reported no remaining Adaptimmune Therapeutics position as of Q2 2021 after selling out during the quarter.
  • QS Investors sold 138,000 Adaptimmune Therapeutics shares in Q2 2021, an estimated $733K.
  • QS Investors first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 1 quarter.
  • QS Investors's Adaptimmune Therapeutics position peaked at $733K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.